Avidity Biosciences — Investor Day (March 2025)
32 slides from Avidity Biosciences's investor day presentation, Mar 17, 2025
Slide 1: Investor & Analyst Event: Transforming Duchenne Muscular Dystrophy
1 March 17, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Transforming Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44® Phase 1/2 Topline Data
Slide 2: Forward-looking statements
2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include, but are not
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Yannick, living with DMD
Slide 4: Three Programs Moving to Commercialization
4 Three Programs Moving to Commercialization Lee Living with DMD, and his mother, Ginne Jeannine Living with DM1 Russell Living with FSHD Del-desiran in DM1 • ~80,000 patients in U.S. and E.U. • On track to be the first globally approved drug for DM1 Del-brax in FSHD • ~45,000-87,000 patients in U.S
Slide 5: Consistent and Reproducible Results Across Rare Neuromuscular Programs
5 Consistent and Reproducible Results Across 3 Rare Neuromuscular Programs Product Candidate Functional Improvement Agreed Regulatory Path Registrational Program Ongoing Q4 2025 Expected Q2 2025 Del-zota Duchenne Muscular Dystrophy (DMD44) Del-desiran Myotonic Dystrophy Type 1 (DM1) Del-brax Faciosc
Slide 6: Today's Update
6 Today’s Update Topline data from Phase 1/2 EXPLORE44® trial • Unprecedented dystrophin production consistent across both doses • Favorable safety and tolerability in both doses • 5mg/kg Q6W dose selected On track for Avidity’s first BLA submission year end 2025 for US accelerated approval • Dystro
Slide 7: Topline Phase 1/2 Data Confirms Potential for Del-zota
7 Topline Phase 1/2 Data Confirms Potential for Del-zota to Improve the Lives of People Living with DMD44 • Doubled participant exposures since August 2024 update • Favorable safety and tolerability consistent across all doses • 5mg/kg Q6W dose selected • Consistent delivery of PMO of ~200 nM in ske
Slide 8: Today's Presenters
8Transforming the Treatment of DMD Sarah Boyce President & CEO Steve Hughes, MD Chief Medical Officer Michael MacLean Chief Financial Officer Kevin Flanigan, MD Director, Center for Gene Therapy, and Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research, Nationwide Children’s
Slide 9: Agenda/Outline
9 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Transforming the Treatment of DMD44 Steve Hughes, M.D., CMO Closing Remarks Sarah Boyce, President & CEO Q&A Session Avidity Management and Husam Younis, PharmD, PhD, with Kevin Flanigan, M.D. Moderator: Mike MacLean,
Slide 10: DMD is a Relentless Hereditary Disorder Causing Progressive Muscle Damage
10 DMD is a Relentless Hereditary Disorder Causing Progressive, Debilitating Muscle Damage • Monogenic, X-linked, recessive condition characterized by progressive muscle damage and weakness • Primarily affects males, loss of ambulation by teenage years • Significantly reduces life expectancy • Cause
Slide 11: Near Full-Length Dystrophin Retains Key Functional Domains
11 Near Full-Length Dystrophin Retains Key Functional Domains and May Offer Improved Muscle Protection for People Living with DMD44 Naturally occurring dystrophin Representative dystrophin produced by del-zota Representative micro-dystrophin produced by gene therapies N H1 R1 R2 R3 H2 R 24 H4 CR N H
Slide 12: Del-zota Potentially Sets a New Standard for Treatment of DMD44
12 Del-zota Potentially Sets a New Standard for the Treatment of DMD44 • Production of near-full length dystrophin • Reduction of muscle damage as evidenced by CK reductions • Sustained treatment effect on CK reduction • Ease of administration • Family friendly Q6W dosing frequency • Currently evalu
Slide 13: Rapidly Executing Toward Del-zota Accelerated Approval
13 Rapidly Executing Toward Del-zota Accelerated Approval • EXPLORE44® trial now complete • Total number of participants enrolled in EXPLORE44-OLE : 39 • Planned BLA submission year end 2025 3: 1 Ra nd om iz at io n D el -z ot a: P la ce bo A Healthy Volunteer Cohorts B2 10 mg/kg Q8W Dose – dose lis
Slide 14: EXPLORE44 Phase 1/2 DMD44 Cohorts: Overview & Objectives
14 EXPLORE44® Phase 1/2 DMD44 Cohorts: Overview & Objectives • Measures of muscle function • PROs • HRQoL Key Exploratory ObjectivesKey Information • Pharmacokinetics • Pharmacodynamics • Exon 44 skipping • Dystrophin protein levels Secondary ObjectivesPrimary Objective • Safety and tolerability of
Slide 15: EXPLORE44: Demographics and Baseline Characteristics
15 EXPLORE44® : Demographics and Baseline Characteristics Data are presented as mean (SD) unless indicated otherwise. *Represents 7 additional genotypes. Placebo N=7 Del-Zota 5 mg/kg N=9 Del-Zota 10 mg/kg N=10 Age (yrs) 13.6 (3.5) 16.0 (4.7) 10.8 (2.7) Body Mass Index (kg/m2) 26.4 (8.4) 24.2 (5.6) 1
Slide 16: Del-zota Showed Favorable Safety and Tolerability
16 Del-zota Showed Favorable Safety and Tolerability in Participants with DMD44 EXPLORE44® : Most TEAEs were mild or moderate • Most common TEAEs occurring in ≥ 3 participants in the del-zota arms include procedural pain and headache • 1 participant discontinued due to serious AE of anaphylaxis • 1
Slide 17: Consistent and High PMO Muscle Concentrations
17 Treatment with Del-zota Resulted in Consistent and High PMO Muscle Concentrations in Participants with DMD44 0 50 100 150 200 250 [P M O 44 in m us cl e tis su e] n M 5 mg/kg Q6W N=7 10 mg/kg Q8W N=10 Muscle biopsy from biceps brachii was collected 28 days post-3rd dose (Day 113/141 for 5/10 mg/k
Slide 18: Significant Exon Skipping in Participants with DMD44
18 Treatment with Del-zota Led to Significant Exon 44 Skipping in Participants with DMD44 37% 43% Exon 44 skipping was measured via ddPCR. Mean ± SEM. Doses expressed as PMO component. *p<0.05 (Wilcoxon test). ddPCR, droplet digital polymerase chain reaction Tx, treatment Baseline Post-Tx Baseline P
Slide 19: Dystrophin Production by ~25% of Normal
19 Del-zota Significantly Increased Dystrophin Production by ~25% of Normal in Participants With DMD44 Unadjusted for muscle content. Dystrophin protein in biceps brachii was measured by western blot and normalized to myosin heavy chain. Mean ± SEM. Dystrophin <1% (BLQ) was imputed as zero (*p<0.05,
Slide 20: Sustained Decreases in Creatine Kinase Levels to Near Normal
20 Del-zota Produced Sustained Decreases in Creatine Kinase Levels to Near Normal at Both Dose Levels Tested In both dose groups, creatine kinase levels were rapidly reduced by greater than 80% compared to baseline to near normal levels and were sustained. ULN shown is 251 and is dependent on age of
Slide 21: Placebo Crossover Participants Saw Rapid Reductions in CK
21 Participants Crossing Over from Placebo to Del-zota saw Rapid and Sustained Reductions in CK levels of >80% from Baseline ULN shown is 251 and is dependent on age of participant – for this study it ranged from 178-251. ULN, upper limit of normal. Del-zota Produced Significant and Sustained Reduct
Slide 22: Dystrophin and CK Results Regardless of Ambulatory Status
22ULN shown is 251 and is dependent on age of participant – for this study it ranged from 178-251. MHC, myosin heavy chain; ULN, upper limit of normal. Both ambulatory and non-ambulatory participants saw increased dystrophin production and reduction in CK levels following del-zota treatment Del-zota
Slide 23: Lowering of CK, ALT, AST, and Myoglobin to Near-normal Levels
23 Treatment with Del-zota Resulted in Lowering of CK, ALT, AST, and Myoglobin to Near-normal Levels 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 0 50 100 150 200 250 300 350 400 450 Study Day A LT (I U /L ) M ed ia n (IQ R) ULN ALT 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 0 50 1
Slide 24: Agenda/Outline
24 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Transforming the Treatment of DMD44 Steve Hughes, M.D., CMO Closing Remarks Sarah Boyce, President & CEO Q&A Session Avidity Management and Husam Younis, PharmD, PhD, with Kevin Flanigan, M.D. Moderator: Mike MacLean,
Slide 25: Topline Phase 1/2 Data Confirms Potential for Del-zota
25 Topline Phase 1/2 Data Confirms Potential for Del-zota to Improve the Lives of People Living with DMD44 • Doubled participant exposures since August 2024 update • Favorable safety and tolerability consistent across all doses • 5mg/kg Q6W dose selected • Consistent delivery of PMO of ~200 nM in sk
Slide 26: Del-zota is the First AOC in Avidity's DMD Franchise
26 Del-zota is the First AOC in Avidity’s DMD Franchise We understand the responsibility to get treatments to patients as quickly as possible • FDA has granted del-zota Orphan Drug, Fast Track and Rare Pediatric Disease designations. EMA has granted del-zota Orphan designation • Alignment with FDA o
Slide 27: Del-zota is on Track to be Avidity's First Commercial Launch
27 Del-zota is on Track to be Avidity’s First Commercial Launch Launch Preparations Del-zota sets the foundation for sequential neuromuscular launches Alignment on Regulatory Path Accelerated Approval path open for del-zota – anticipate BLA filing at year end 2025 Commercial Launch in U.S. Team in p
Slide 28: Preparations to Launch Three Drugs Well Underway
28 Preparations to Launch Three Drugs Well Underway Community Engagement • Leveraging established relationships with patients, clinicians, and others to execute our rapid go-to-market strategy All-Star Rare Disease Team • Experienced rare disease leadership team in place to execute patient-centric p
Slide 29: Our Vision
29 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Nathan, living with DMD, and his mother, Misty
Slide 30: Q&A
30 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Transforming Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44® Phase 1/2 Topline Data Q&A March 17, 2025
Slide 31: Kevin M. Flanigan, M.D.
31 Kevin M. Flanigan, M.D. Director, Center for Gene Therapy, and Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research, Nationwide Children’s Hospital Professor of Pediatrics and Neurology, Ohio State University Dr. Flanigan is the Director of the Center for Gene Therapy at
Slide 32: Investor & Analyst Event: Transforming Duchenne Muscular Dystrophy
32 March 17, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Transforming Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44® Phase 1/2 Topline Data